Kiniksa Pharmaceuticals Ltd (KNSA) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $78.55 (-0.98%), Market cap $4.13B, P/E ratio 58.95, 52-week low–high $25.95 ~ $59.48.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Phar
Financial statements, price targets, institutional (13F) holdings and related news for Kiniksa Pharmaceuticals Ltd are updated in real time on BlackAll Trade.
Kiniksa Pharmaceuticals Ltd trades at $78.55 (-0.98%). Real-time quotes and charts are available on BlackAll Trade.
Kiniksa Pharmaceuticals Ltd has a market cap of about $4.13B. Its P/E ratio is 58.95.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers